Procter & Gamble Health Limited EBIT

The latest EBIT for PGHL.BO is $4.9B as of June 2026. That compares with $3.6B in the prior-year period — up 35.1% year over year. That is below the sector sector average of $2.5T. Investors often review this figure alongside Procter & Gamble Health Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, PGHL.BO's EBIT moved from $3.6B to $4.9B — a 35.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Procter & Gamble Health Limited's operating scale or balance-sheet position.

Against its sector companies, PGHL.BO currently prints $4.9B for EBIT, while the sector average sits near $2.5T. That is roughly 99.8% below the sector mean. Large gaps often invite a closer look at Procter & Gamble Health Limited's growth, margins, and balance sheet.

A EBIT figure of $4.9B for PGHL.BO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.5T. Explore the charts below for those layers of context.

After noting PGHL.BO's EBIT ($4.9B), review year-over-year change from $3.6B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.